brequinar + dipyridamole

A combination of **brequinar**, a potent oral dihydroorotate dehydrogenase (DHODH) inhibitor, and **dipyridamole**, an inhibitor of equilibrative nucleoside transporters (ENT1/2/4), designed to deplete intracellular pyrimidine nucleotide pools through dual inhibition of de novo and salvage pyrimidine synthesis. This combination exhibits **synergistic antiviral activity in vitro** against SARS-CoV-2 (including Beta and Delta variants) by disrupting host nucleotide metabolism required for viral RNA replication. Brequinar has also been studied in oncology and autoimmune indications, while dipyridamole is an approved antiplatelet agent with established clinical use. Joint use is being explored as a **host-acting antiviral therapy**, particularly for COVID-19, aiming to limit resistance by targeting host, not viral, pathways[1][2][3].

Brand names

None known specific to the combination

Other names

brequinar + DPY